Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 137-142

  Segura, Pedro Pérez ^a   Gil, Miguel ^b   Balañá, Carmen ^c   Chacón, Ignacio ^d   Langa, José Muñoz ^e   Martín, María ^f   Bruna, Jordi ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Leptomeningeal metastasis; Solid tumors; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FEMALE; GAIT DISORDER; HORMONAL THERAPY; HUMAN; HYPESTHESIA; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MALE; MENINGEAL METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RETCHING; RHINOPHARYNGITIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84864277822     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0879-3     Document Type: Article

References (28)

1. MC Chamberlain 2010 Leptomeningeal metastasis Curr Opin Oncol 22 627 635 20689429 10.1097/CCO.0b013e32833de986
2. F Clatot G Philippin-Lauridant MJ Ouvrier, et al. 2009 Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy J Neurooncol 95 421 426 19557501 10.1007/s11060-009-9940-2 1:CAS:528:DC%2BD1MXhtlKitbrE
3. MD Groves 2011 Leptomeningeal disease Neurosurg Clin N Am 22 67 78 21109151 10.1016/j.nec.2010.08.006
4. MD Groves 2010 New strategies in the management of leptomeningeal metastases Arch Neurol 67 305 312 20212228 10.1001/archneurol.2010.18
5. P Beauchesne 2010 Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours Lancet Oncol 11 871 879 20598636 10.1016/S1470-2045(10)70034-6 1:CAS:528:DC%2BC3cXhtFWqsrzO
6. MC Chamberlain 2010 Leptomeningeal metastasis Semin Neurol 30 236 244 20577930 10.1055/s-0030-1255220
7. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008) Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008:CD007415
8. LE Abrey C Christodoulou 2001 Temozolomide for treating brain metastases Semin Oncol 28 34 42 11550137 10.1016/S0093-7754(01)90069-7 1:CAS:528: DC%2BD3MXntFGht7o%3D (Pubitemid 32879944)
9. LE Abrey MP Mehta 2003 Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide Clin Adv Hematol Oncol 1 231 236 16224412
10. W Boogerd GC de Gast O Dalesio 2007 Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 109 306 312 17149755 10.1002/cncr.22411 1:CAS:528:DC%2BD2sXhs1yrsLo%3D (Pubitemid 46106245)
11. S Siena L Crino M Danova, et al. 2010 Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study Ann Oncol 21 655 661 19767314 10.1093/annonc/mdp343 1:STN:280:DC%2BC3c7isVGmsA%3D%3D
12. E Verger M Gil R Yaya N Vinolas, et al. 2005 Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial Int J Radiat Oncol Biol Phys 61 185 191 15629610 10.1016/j.ijrobp.2004.04.061 1:CAS:528:DC%2BD2MXjsVCr (Pubitemid 40039121)
13. JJ Olson NA Paleologos LE Gaspar, et al. 2010 The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics J Neurooncol 96 115 142 19957013 10.1007/s11060-009-0058-3 1:CAS:528:DC%2BC3cXps1SrsQ%3D%3D
14. VA Trinh SP Patel WJ Hwu 2009 The safety of temozolomide in the treatment of malignancies Expert Opin Drug Saf 8 493 499 19435405 10.1517/ 14740330902918281 1:CAS:528:DC%2BD1MXns1CgsLw%3D
15. M Garcia A Clopes J Bruna M Martinez E Fort M Gil 2009 Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations Cancer Manag Res 1 137 150 21188132 10.2147/CMR.S5598 1:CAS:528:DC%2BD1MXhsVGqu77J
16. L Tentori G Graziani 2009 Recent approaches to improve the antitumor efficacy of temozolomide Curr Med Chem 16 245 257 19149575 10.2174/ 092986709787002718 1:CAS:528:DC%2BD1MXjsFGqs78%3D
17. S Ostermann C Csajka T Buclin, et al. 2004 Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 3728 3736 15173079 10.1158/1078-0432.CCR-03-0807 1:CAS:528:DC%2BD2cXksVKntrw%3D (Pubitemid 38697606)
18. Q Zhou P Guo GD Kruh P Vicini X Wang JM Gallo 2007 Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition Clin Cancer Res 13 4271 4279 17634557 10.1158/1078-0432.CCR- 07-0658 1:CAS:528:DC%2BD2sXnvVChtrw%3D (Pubitemid 47105992)
19. M Patel C McCully K Godwin FM Balis 2003 Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates J Neurooncol 61 203 207 12675312 10.1023/A:1022592913323 (Pubitemid 36342297)
20. N Mutter R Stupp 2006 Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6 1187 1204 10.1586/14737140.6.8.1187 1:CAS:528:DC%2BD28XpslGhsLc%3D (Pubitemid 44304687)
21. E Franceschi G Cavallo L Scopece, et al. 2005 Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis J Neurooncol 73 261 264 15980977 10.1007/s11060-004-5672-5 (Pubitemid 40974022)
22. AL Hoffmann JH Buhk H Strik 2009 Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide Anticancer Res 29 5191 5195 20044635 1:CAS:528:DC%2BC3cXht1Kjsrk%3D
23. GY Ku G Krol DH Ilson 2007 Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan J Clin Oncol 25 e14 e16 17470852 10.1200/JCO.2006.10.3317
24. G Lombardi F Zustovich A Della Puppa, et al. 2010 Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma J Neurooncol 104 381 386 21140282 10.1007/s11060-010-0484-2
25. A Salmaggi A Silvani M Eoli E Lamperti A Boiardi 2002 Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report Neurol Sci 23 257 258 12528690 10.1007/s100720200053 1:STN:280:DC%2BD3s%2FitFKqtw%3D%3D (Pubitemid 36024573)
26. M Zauderer LM Krug MC Pietanza D O'Rourke 2010 Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy J Thorac Oncol 5 1716 1717 20871272 10.1097/JTO.0b013e3181f1cc32
27. TH Davis CE Fadul MJ Glantz, et al. 2003 Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report Proc Am Soc Clin Oncol 22 115 10.1200/JCO.2004.07.165
28. Grewal J, Saria MG, Kesari S (2011) Novel approaches to treating leptomeningeal metastases. J Neurooncol 106(2):225-234